Patents by Inventor Michael Raymond Batzloff

Michael Raymond Batzloff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOGENIC PEPTIDE AGAINST GROUP A STREPTOCOCCUS
    Publication number: 20230382981
    Abstract: A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.
    Type: Application
    Filed: May 24, 2023
    Publication date: November 30, 2023
    Applicant: GRIFFITH UNIVERSITY
    Inventors: Michael F. GOOD, Manisha PANDEY, Michael Raymond BATZLOFF
  • Immunogenic peptide against group a
    Patent number: 11732033
    Abstract: A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A Streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 5 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: August 22, 2023
    Assignee: GRIFFITH UNIVERSITY
    Inventors: Michael F. Good, Manisha Pandey, Michael Raymond Batzloff
  • IMMUNOGENIC PEPTIDE AGAINST GROUP A STREPTOCOCCUS
    Publication number: 20210024619
    Abstract: A modified p145 peptide having enhanced mucosal immunogenicity for use in eliciting a mucosal immune response to group A Streptococcal bacteria in a mammal such as a human. Intramuscular administration of the modified p145 5 peptide may be particularly efficacious. An S2 peptide or variant may be co-administered with the modified p145 peptide to enhance the immune response.
    Type: Application
    Filed: August 22, 2018
    Publication date: January 28, 2021
    Applicant: GRIFFITH UNIVERSITY
    Inventors: Michael F. GOOD, Manisha PANDEY, Michael Raymond BATZLOFF
  • Vaccine
    Publication number: 20080175868
    Abstract: Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.
    Type: Application
    Filed: July 24, 2007
    Publication date: July 24, 2008
    Applicants: ID Biomedical Corporation of Quebec, The Council of the Queensland Institute of Medical Research
    Inventors: George H. Lowell, George L. White, Michael Raymond Batzloff, David S. Burt, Tomas B. Leanderson, Michael F. Good